Key Cardiovascular Trials for Canakinumab
Canakinumab, Novartis's IL-1β inhibitor primarily approved for rare autoinflammatory diseases, was tested in cardiovascular outcomes trials targeting inflammation's role in atherosclerosis and events like heart attacks.
CANTOS Trial Details
The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) enrolled 10,061 patients post-myocardial infarction with elevated hsCRP (>2 mg/L) and persistent inflammation despite statin therapy. Patients received subcutaneous canakinumab (50 mg, 150 mg, or 300 mg every 12 weeks) or placebo. It met its primary endpoint, reducing the composite of cardiovascular death, nonfatal MI, stroke, or hospitalization for unstable angina by 15-20% (dose-dependent), driven by fewer MIs and cardiovascular deaths. hsCRP dropped significantly without affecting LDL cholesterol. Published in NEJM 2017.[1]
Why CANTOS Matters for Cardio Use
CANTOS provided proof-of-concept that targeting inflammation (not lipids) reduces recurrent CV events, influencing trials like those for colchicine. Novartis did not pursue CV approval due to infection risks (dose-dependent fatal infections higher vs. placebo).[1][2]
Related Canakinumab CV Trials
- CLEAR Outcomes: Post hoc analysis in type 2 diabetes patients with CV history; canakinumab reduced MACE similarly to CANTOS, with benefits in high-inflammation subgroups. Supports anti-inflammatory strategy in diabetes-CV overlap.[3]
- Ongoing or Smaller Studies: Phase 2/3 trials like NCT03044423 (canakinumab in post-ACS patients) and extensions from CANTOS (e.g., NCT02227573) explored long-term effects. No new large-scale primary prevention trials reported.
Safety Concerns from Trials
In CANTOS, serious infections occurred in 1.0-1.7% more patients on canakinumab vs. placebo; neutropenia was dose-related. No overall mortality benefit, but CV mortality dropped 18%. Patients with hsCRP >2 mg/L gained most benefit.[1]
Comparison to Other Anti-Inflammatory CV Drugs
Unlike canakinumab (biologic, expensive, subcutaneous), oral options like colchicine (COLCOT, LoDoCo2 trials) showed similar MACE reductions with lower cost but gastrointestinal side effects.[4]
[1]: NEJM - CANTOS Trial (2017)
[2]: Circulation - CANTOS Follow-up
[3]: Lancet Diabetes Endocrinol - CLEAR Analysis (2021)
[4]: NEJM - COLCOT (2019)